Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pelabresib + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pelabresib + ruxolitinib is a combination therapy currently evaluated for the treatment of myelofibrosis in patients who have not previously received a JAK inhibitor. Pelabresib is an oral, small molecule inhibitor of bromodomain and extraterminal domain (BET) proteins, targeting epigenetic regulation of genes involved in inflammation and fibrosis. Ruxolitinib is an oral, small molecule inhibitor of Janus kinase 1 and 2 (JAK1, JAK2), blocking pro-inflammatory signaling pathways. The dual inhibition demonstrated additive benefits in clinical trials, significantly increasing spleen volume reduction, improving symptom scores, and potentially modifying disease biology by reducing pro-inflammatory cytokine levels and improving bone marrow morphology compared with ruxolitinib alone[1][2][3][4][5][6].
- Brand names
- Jakafi (ruxolitinib)
- Other names
- pelabresib plus ruxolitinibBET inhibitor plus JAK inhibitor
02
Targets
Beyond the preview
Go deeper on pelabresib + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pelabresib + ruxolitinib.